{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:23:51Z","timestamp":1793618631858,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Independent Research Fund Denmark","award":["10.46540\/3165-00227B"],"award-info":[{"award-number":["10.46540\/3165-00227B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01393-4","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:14:29Z","timestamp":1772442869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Ask Tybj\u00e6rg","family":"Nordestgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMOA1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMOA1801174.","journal-title":"N Engl J Med"},{"key":"1393_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/EURHEARTJ\/EHAA099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC, L\u00fcscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42:113\u201331. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAA099.","journal-title":"Eur Heart J"},{"key":"1393_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249.","journal-title":"Circ Res"},{"key":"1393_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/J.JACC.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404\u201310. https:\/\/doi.org\/10.1016\/J.JACC.2012.10.027.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMOA1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMOA1707914.","journal-title":"N Engl J Med"},{"key":"1393_CR6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMOA1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMOA1912388.","journal-title":"N Engl J Med"},{"key":"1393_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMOA2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMOA2021372.","journal-title":"N Engl J Med"},{"key":"1393_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, et al. <article-title update=\"added\">2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic\u00a0coronary disease. J Am Coll Cardiol. 2023;82:833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/EURHEARTJ\/EHAE177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415\u2013537. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAE177.","journal-title":"Eur Heart J"},{"key":"1393_CR10","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/JAMA.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268\u201380. https:\/\/doi.org\/10.1001\/JAMA.2020.22258.","journal-title":"JAMA"},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"1393_CR12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart J-C, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with Pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard AT, Tybj\u00e6rg-Hansen A, Mansbach H, Kersten S, Nordestgaard BG, Rosenson RS. Target populations for novel triglyceride-lowering therapies. J Am Coll Cardiol. 2025;85:1876\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.035.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/S41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524\u201333. https:\/\/doi.org\/10.1038\/S41586-021-03392-8.","journal-title":"Nature"},{"key":"1393_CR15","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003008.","journal-title":"Circulation"},{"key":"1393_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/CLINCHEM.2018.294926","volume":"65","author":"SEJ Hansen","year":"2019","unstructured":"Hansen SEJ, Madsen CM, Varbo A, Nordestgaard BG. Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem. 2019;65:321\u201332. https:\/\/doi.org\/10.1373\/CLINCHEM.2018.294926.","journal-title":"Clin Chem"},{"key":"1393_CR17","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"key":"1393_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/S41569-022-00676-Y","volume":"19","author":"J Bor\u00e9n","year":"2022","unstructured":"Bor\u00e9n J, Taskinen MR, Bj\u00f6rnson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022;19:577\u201392. https:\/\/doi.org\/10.1038\/S41569-022-00676-Y.","journal-title":"Nat Rev Cardiol"},{"key":"1393_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/01.atv.11.3.569","volume":"11","author":"M Shaikh","year":"1991","unstructured":"Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb Vasc Biol. 1991;11:569\u201377. https:\/\/doi.org\/10.1161\/01.atv.11.3.569.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.atv.12.1.6","volume":"12","author":"BG Nordestgaard","year":"1992","unstructured":"Nordestgaard BG, Tybjaerg-Hansen A, Lewis B, United States. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb Vasc Biol. 1992;12:6\u201318. https:\/\/doi.org\/10.1161\/01.atv.12.1.6.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1161\/01.atv.8.4.421","volume":"8","author":"BG Nordestgaard","year":"1988","unstructured":"Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8:421\u20138. https:\/\/doi.org\/10.1161\/01.atv.8.4.421.","journal-title":"Arteriosclerosis"},{"key":"1393_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0022-2275(20)38428-5","volume":"29","author":"BG Nordestgaard","year":"1988","unstructured":"Nordestgaard BG, Zilvetsmip DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988;29:1491\u2013500. https:\/\/doi.org\/10.1016\/S0022-2275(20)38428-5.","journal-title":"J Lipid Res"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/NATURE10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317\u201325. https:\/\/doi.org\/10.1038\/NATURE10146.","journal-title":"Nature"},{"key":"1393_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145\u201356. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306656.","journal-title":"Circ Res"},{"key":"1393_CR25","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","volume":"359","author":"J Zacho","year":"2008","unstructured":"Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa0707402.","journal-title":"N Engl J Med"},{"key":"1393_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/JAMA.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybj\u00e6rg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299\u2013308. https:\/\/doi.org\/10.1001\/JAMA.298.3.299.","journal-title":"JAMA"},{"key":"1393_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/JAMA.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309\u201316. https:\/\/doi.org\/10.1001\/JAMA.298.3.309.","journal-title":"JAMA"},{"key":"1393_CR28","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/JAMA.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993. https:\/\/doi.org\/10.1001\/JAMA.2009.1619.","journal-title":"JAMA"},{"issue":"22","key":"1393_CR29","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1161\/01.CIR.99.22.2901","volume":"99","author":"HH Wittrup","year":"1999","unstructured":"Wittrup HH, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation. 1999;99(22):2901\u20137. https:\/\/doi.org\/10.1161\/01.CIR.99.22.2901.","journal-title":"Circulation"},{"key":"1393_CR30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","volume":"96","author":"BG Nordestgaard","year":"1997","unstructured":"Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybj\u00e6rg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737\u201344. https:\/\/doi.org\/10.1161\/01.CIR.96.6.1737.","journal-title":"Circulation"},{"key":"1393_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/JAMA.2017.0972","volume":"317","author":"AV Khera","year":"2017","unstructured":"Khera AV, Won HH, Peloso GM, O\u2019Dushlaine C, Liu D, Stitziel NO, et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA. 2017;317:937\u201346. https:\/\/doi.org\/10.1001\/JAMA.2017.0972.","journal-title":"JAMA"},{"key":"1393_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMOA1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341. https:\/\/doi.org\/10.1056\/NEJMOA1308027.","journal-title":"N Engl J Med"},{"key":"1393_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med United States. 2014;371:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med United States"},{"key":"1393_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMOA1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1612790.","journal-title":"N Engl J Med"},{"key":"1393_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMOA1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123\u201333. https:\/\/doi.org\/10.1056\/NEJMOA1510926.","journal-title":"N Engl J Med"},{"key":"1393_CR36","doi-asserted-by":"publisher","unstructured":"Stitziel N, Stirrups K, Masca N, J E, PG F, IR K, et al. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med. N Engl J Med; 2016;374:1134\u201344. https:\/\/doi.org\/10.1056\/NEJMOA1507652","DOI":"10.1056\/NEJMOA1507652"},{"key":"1393_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/J.JACC.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336. https:\/\/doi.org\/10.1016\/J.JACC.2012.08.1026.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHS431","author":"AB J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHS431.","journal-title":"Eur Heart J"},{"key":"1393_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345. https:\/\/doi.org\/10.1056\/NEJM198711123172001.","journal-title":"N Engl J Med"},{"key":"1393_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/J.0954-6820.1988.TB15891.X","volume":"223","author":"LA Carlson","year":"1988","unstructured":"Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405\u201318. https:\/\/doi.org\/10.1111\/J.0954-6820.1988.TB15891.X.","journal-title":"Acta Med Scand"},{"key":"1393_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410\u20138. https:\/\/doi.org\/10.1056\/NEJM199908053410604.","journal-title":"N Engl J Med"},{"key":"1393_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"S Behar","year":"2000","unstructured":"Behar S, Brunner D, Kaplinsky E, Mandelzweig L, Benderly M. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21\u20137. https:\/\/doi.org\/10.1161\/01.CIR.102.1.21.","journal-title":"Circulation"},{"key":"1393_CR43","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet Lancet. 2005;366:1849\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2.","journal-title":"Lancet Lancet"},{"key":"1393_CR44","doi-asserted-by":"publisher","unstructured":"Boden W, Probstfield J, Anderson T, BR C, P D-N, K K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. N Engl J Med; 2011;365:2255\u201367. https:\/\/doi.org\/10.1056\/NEJMOA1107579","DOI":"10.1056\/NEJMOA1107579"},{"key":"1393_CR45","doi-asserted-by":"publisher","unstructured":"Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. N Engl J Med; 2014;371:203\u201312. https:\/\/doi.org\/10.1056\/NEJMOA1300955","DOI":"10.1056\/NEJMOA1300955"},{"key":"1393_CR46","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMOA1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374. https:\/\/doi.org\/10.1056\/NEJMOA1001282.","journal-title":"N Engl J Med"},{"key":"1393_CR47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMOA1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379:1540\u201350. https:\/\/doi.org\/10.1056\/NEJMOA1804989.","journal-title":"N Engl J Med"},{"key":"1393_CR48","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMOA2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med. 2025;393:1279\u201391. https:\/\/doi.org\/10.1056\/NEJMOA2507227.","journal-title":"N Engl J Med"},{"key":"1393_CR49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"key":"1393_CR50","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/ATVBAHA.120.315639","volume":"41","author":"MO Johansen","year":"2021","unstructured":"Johansen MO, Vedel-Krogh S, Nielsen SF, Afzal S, Smith GD, Nordestgaard BG. Per-particle triglyceride-rich lipoproteins imply higher myocardial infarction risk than low-density lipoproteins: Copenhagen general population study. Arterioscler Thromb Vasc Biol Arterioscler Thromb Vasc Biol. 2021;41:2063\u201375. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315639.","journal-title":"Arterioscler Thromb Vasc Biol Arterioscler Thromb Vasc Biol"},{"key":"1393_CR51","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","volume":"44","author":"E Bj\u00f6rnson","year":"2023","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen M-R, Burgess S, Rawshani A, Bor\u00e9n J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44:4186\u201395. https:\/\/doi.org\/10.1093\/eurheartj\/ehad337.","journal-title":"Eur Heart J"},{"key":"1393_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/CLINCHEM\/HVAE222","volume":"71","author":"BN Wadstr\u00f6m","year":"2025","unstructured":"Wadstr\u00f6m BN, Wulff AB, Pedersen KM, Nordestgaard BG. Small remnants versus large triglyceride-rich lipoproteins in risk of atherosclerotic cardiovascular disease. Clin Chem. 2025;71:463\u201373. https:\/\/doi.org\/10.1093\/CLINCHEM\/HVAE222.","journal-title":"Clin Chem"},{"key":"1393_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.119094","author":"LK Kyhl","year":"2025","unstructured":"Kyhl LK, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Smith GD, Nielsen SF. VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction. Atherosclerosis. 2025. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119094.","journal-title":"Atherosclerosis"},{"key":"1393_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/EHJOPEN\/OEAF018","volume":"5","author":"E Gagnon","year":"2025","unstructured":"Gagnon E, Gill D, Burgess S, Arsenault BJ. Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: a drug target Mendelian randomization study. European heart journal open Eur Heart J Open. 2025;5:oeaf018. https:\/\/doi.org\/10.1093\/EHJOPEN\/OEAF018.","journal-title":"European heart journal open Eur Heart J Open"},{"key":"1393_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/J.LANEPE.2025.101223","volume":"51","author":"M Johansen","year":"2025","unstructured":"Johansen M, Vedel-Krogh S, Nielsen SF, Afzal S, Davey Smith G, Nordestgaard BG. Association of remnant cholesterol with unhealthy lifestyle and risk of coronary heart disease: a population-based cohort study. The Lancet Regional Health - Europe. 2025;51:101223. https:\/\/doi.org\/10.1016\/J.LANEPE.2025.101223.","journal-title":"The Lancet Regional Health - Europe"},{"key":"1393_CR56","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1093\/EURHEARTJ\/EHAB293","volume":"42","author":"A Varbo","year":"2021","unstructured":"Varbo A, Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J. 2021;42:4833\u201343. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB293.","journal-title":"Eur Heart J"},{"key":"1393_CR57","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/EURHEARTJ\/EHAB432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42:4324\u201332. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB432.","journal-title":"Eur Heart J"},{"key":"1393_CR58","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/EURJPC\/ZWAE102","volume":"31","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Madsen JM, \u00d6zbek BT, K\u00f8ber L, Bang LE, L\u00f8nborg JT, et al. The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction. Eur J Prev Cardiol. 2024;31:1227\u201337. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAE102.","journal-title":"Eur J Prev Cardiol"},{"key":"1393_CR59","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/J.JACC.2024.12.033","volume":"85","author":"BN Wadstr\u00f6m","year":"2025","unstructured":"Wadstr\u00f6m BN, Borges MC, Wulff AB, Smith GD, Sanderson E, Nordestgaard BG. Elevated remnant and LDL cholesterol and the risk of peripheral artery disease: a Mendelian randomization study. J Am Coll Cardiol J Am Coll Cardiol. 2025;85:1353\u201368. https:\/\/doi.org\/10.1016\/J.JACC.2024.12.033.","journal-title":"J Am Coll Cardiol J Am Coll Cardiol"},{"key":"1393_CR60","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/EURHEARTJ\/EHAB705","volume":"43","author":"BN Wadstr\u00f6m","year":"2022","unstructured":"Wadstr\u00f6m BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2022;43:3258\u201369. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB705.","journal-title":"Eur Heart J"},{"key":"1393_CR61","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","volume":"79","author":"T Doi","year":"2022","unstructured":"Doi T, Langsted A, Nordestgaard BG. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction. J Am Coll Cardiol. 2022;79:2383\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.384.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR62","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/EURHEARTJ\/EHAA172","volume":"41","author":"M Kaltoft","year":"2020","unstructured":"Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020;41:2288\u201399. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAA172.","journal-title":"Eur Heart J"},{"key":"1393_CR63","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/ATVBAHA.123.320175","volume":"44","author":"BN Wadstr\u00f6m","year":"2024","unstructured":"Wadstr\u00f6m BN, Pedersen KM, Wulff AB, Nordestgaard BG. Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apoB: a cohort study. Arterioscler Thromb Vasc Biol. 2024;44:1144\u201355. https:\/\/doi.org\/10.1161\/ATVBAHA.123.320175.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR64","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/EURHEARTJ\/EHAC822","volume":"44","author":"BN Wadstr\u00f6m","year":"2023","unstructured":"Wadstr\u00f6m BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023;44:1432\u201345. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAC822.","journal-title":"Eur Heart J"},{"key":"1393_CR65","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/ATVBAHA.117.310269\/-\/DC1","volume":"38","author":"A Varbo","year":"2018","unstructured":"Varbo A, Nordestgaard BG. Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: two cohort studies of 113 554 individuals. Arterioscler Thromb Vasc Biol. 2018;38:464\u201372. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310269\/-\/DC1.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040039","volume":"14","author":"Q Huang","year":"2025","unstructured":"Huang Q, Qiu W, Chen C, Wang J, Ou Y, Feng Y. Relationship between remnant cholesterol and risk of heart failure in a community population without cardiovascular disease: results of the China Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project. J Am Heart Assoc. 2025;14:e040039. https:\/\/doi.org\/10.1161\/JAHA.124.040039.","journal-title":"J Am Heart Assoc"},{"key":"1393_CR67","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/EURJPC\/ZWAC286","volume":"30","author":"A Cordero","year":"2023","unstructured":"Cordero A, Alvarez-Alvarez B, Escribano D, Garc\u00eda-Acu\u00f1a JM, Cid-Alvarez B, Rodr\u00edguez-Ma\u00f1ero M, et al. Remnant cholesterol in patients admitted for acute coronary syndromes. Eur J Prev Cardiol. 2023;30:340\u20138. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAC286.","journal-title":"Eur J Prev Cardiol"},{"key":"1393_CR68","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/CLINCHEM\/HVAA269","volume":"67","author":"LT Nordestgaard","year":"2021","unstructured":"Nordestgaard LT, Christoffersen M, Afzal S, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Frikke-Schmidt R. Triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease: a study of 125 727 individuals. Clin Chem. 2021;67:245\u201355. https:\/\/doi.org\/10.1093\/CLINCHEM\/HVAA269.","journal-title":"Clin Chem"},{"key":"1393_CR69","doi-asserted-by":"publisher","first-page":"E645","DOI":"10.9778\/CMAJO.20210318","volume":"11","author":"OR Weaver","year":"2023","unstructured":"Weaver OR, Krysa JA, Ye M, Vena JE, Eurich DT, Proctor SD. Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study. CMAJ Open. 2023;11:E645-53. https:\/\/doi.org\/10.9778\/CMAJO.20210318.","journal-title":"CMAJ Open"},{"key":"1393_CR70","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/EURJPC\/ZWAD036","volume":"30","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Kim SE, Go TH, Kang DR, Jeon HS, Kim YI, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and incident cardiovascular disease among Koreans: a national population-based study. Eur J Prev Cardiol. 2023;30:1142\u201350. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAD036.","journal-title":"Eur J Prev Cardiol"},{"key":"1393_CR71","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jacc.2024.06.035","volume":"84","author":"D Zahger","year":"2024","unstructured":"Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, et al. Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome. J Am Coll Cardiol. 2024;84:994\u20131006. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.035.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/EURHEARTJ\/EHZ767","volume":"41","author":"PR Lawler","year":"2020","unstructured":"Lawler PR, Kotrri G, Koh M, Goodman SG, Farkouh ME, Lee DS, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020;41:86\u201394. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ767.","journal-title":"Eur Heart J"},{"key":"1393_CR73","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/CVR\/CVAC124","volume":"119","author":"Y Wang","year":"2023","unstructured":"Wang Y, Fang Y, Magliano DJ, Charchar FJ, Sobey CG, Drummond GR, et al. Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovasc Res. 2023;119:826\u201334. https:\/\/doi.org\/10.1093\/CVR\/CVAC124.","journal-title":"Cardiovasc Res"},{"key":"1393_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-023-01921-5","volume":"22","author":"FPB Kristensen","year":"2023","unstructured":"Kristensen FPB, Christensen DH, Mortensen MB, Maeng M, Kahlert J, S\u00f8rensen HT, et al. Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study. Cardiovasc Diabetol. 2023;22:187. https:\/\/doi.org\/10.1186\/S12933-023-01921-5.","journal-title":"Cardiovasc Diabetol"},{"key":"1393_CR75","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.2337\/DC21-2511","volume":"45","author":"L Fu","year":"2022","unstructured":"Fu L, Tai S, Sun J, Zhang N, Zhou Y, Xing Z, et al. Remnant cholesterol and its visit-to-visit variability predict cardiovascular outcomes in patients with type 2 diabetes: findings from the ACCORD cohort. Diabetes Care. 2022;45:2136\u201343. https:\/\/doi.org\/10.2337\/DC21-2511.","journal-title":"Diabetes Care"},{"key":"1393_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-022-01667-6","volume":"21","author":"JH Huh","year":"2022","unstructured":"Huh JH, Han K, Cho YK, Roh E, Kang JG, Lee SJ, et al. Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovasc Diabetol. 2022;21:228. https:\/\/doi.org\/10.1186\/S12933-022-01667-6.","journal-title":"Cardiovasc Diabetol"},{"key":"1393_CR77","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","volume":"76","author":"O Casta\u00f1er","year":"2020","unstructured":"Casta\u00f1er O, Pint\u00f3 X, Subirana I, Amor AJ, Ros E, Hern\u00e1ez \u00c1, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76:2712\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2020.10.008.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/CLINCHEM\/HVAA290","volume":"67","author":"M Johansen","year":"2021","unstructured":"Johansen M, Nielsen SF, Afzal S, Vedel-Krogh S, Davey Smith G, Nordestgaard BG. Very low-density lipoprotein cholesterol may mediate a substantial component of the effect of obesity on myocardial infarction risk: the Copenhagen General Population Study. Clin Chem. 2021;67:276\u201387. https:\/\/doi.org\/10.1093\/CLINCHEM\/HVAA290.","journal-title":"Clin Chem"},{"key":"1393_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-025-56790-1","volume":"16","author":"QW Ren","year":"2025","unstructured":"Ren QW, Teng THK, Ouwerkerk W, Tse YK, Tsang CTW, Wu MZ, et al. Triglyceride levels and its association with all-cause mortality and cardiovascular outcomes among patients with heart failure. Nat Commun. 2025;16:1408. https:\/\/doi.org\/10.1038\/S41467-025-56790-1.","journal-title":"Nat Commun"},{"key":"1393_CR80","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/EURJPC\/ZWAF104","volume":"22","author":"E Aaseth","year":"2025","unstructured":"Aaseth E, Halvorsen S, Helseth R, Gravning JA. Remnant cholesterol, plasma triglycerides and risk of cardiovascular disease events in young adults: a prospective cohort study. Eur J Prev Cardiol Eur J Prev Cardiol. 2025;22:1181\u20139. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF104.","journal-title":"Eur J Prev Cardiol Eur J Prev Cardiol"},{"key":"1393_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/EURJPC\/ZWAF092","volume":"00","author":"J Riis","year":"2025","unstructured":"Riis J, Nordestgaard BG, Afzal S. High remnant cholesterol and atherosclerotic cardiovascular disease in healthy women and men aged 70\u2013100. Eur J Prev Cardiol. 2025;00:1\u20139. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF092.","journal-title":"Eur J Prev Cardiol"},{"key":"1393_CR82","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","volume":"44","author":"D El\u00edas-L\u00f3pez","year":"2024","unstructured":"El\u00edas-L\u00f3pez D, Vedel-Krogh S, Kobylecki CJ, Wadstr\u00f6m BN, Nordestgaard BG. Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort study. Arterioscler Thromb Vasc Biol. 2024;44:2647\u201358. https:\/\/doi.org\/10.1161\/ATVBAHA.124.321387.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR83","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJM199704033361401","volume":"336","author":"PM Ridker","year":"1997","unstructured":"Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973\u20139. https:\/\/doi.org\/10.1056\/NEJM199704033361401.","journal-title":"N Engl J Med"},{"key":"1393_CR84","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0140-6736(97)09032-6","volume":"351","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(97)09032-6.","journal-title":"Lancet"},{"key":"1393_CR85","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, Lippincott Williams and Wilkins. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767\u201372. https:\/\/doi.org\/10.1161\/01.CIR.101.15.1767.","journal-title":"Circulation"},{"key":"1393_CR86","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836\u201343. https:\/\/doi.org\/10.1056\/NEJM200003233421202.","journal-title":"N Engl J Med"},{"key":"1393_CR87","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"S Kaptoge","year":"2010","unstructured":"Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet Lancet. 2010;375:132\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(09)61717-7.","journal-title":"Lancet Lancet"},{"key":"1393_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/JAMA.2009.954","volume":"302","author":"P Elliott","year":"2009","unstructured":"Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37\u201348. https:\/\/doi.org\/10.1001\/JAMA.2009.954.","journal-title":"JAMA"},{"key":"1393_CR89","doi-asserted-by":"publisher","unstructured":"Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. The Lancet. Elsevier B.V.; 2012;379:1205\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(11)61931-4","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"1393_CR90","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"DI Swerdlow","year":"2012","unstructured":"Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214. https:\/\/doi.org\/10.1016\/S0140-6736(12)60110-X.","journal-title":"Lancet"},{"key":"1393_CR91","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959\u201365. https:\/\/doi.org\/10.1056\/NEJM200106283442601.","journal-title":"N Engl J Med"},{"key":"1393_CR92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20. https:\/\/doi.org\/10.1056\/NEJMoa042378.","journal-title":"N Engl J Med"},{"key":"1393_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMOA042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29\u201338. https:\/\/doi.org\/10.1056\/NEJMOA042000.","journal-title":"N Engl J Med"},{"key":"1393_CR94","doi-asserted-by":"publisher","unstructured":"Jolly SS, d\u2019Entremont M-A, Lee SF, Mian R, Tyrwhitt J, Kedev S, et al. Colchicine in Acute Myocardial Infarction. New Eng J Med. Massachusetts Medical Society; 2025;292:633\u201342. https:\/\/doi.org\/10.1056\/NEJMOA2405922","DOI":"10.1056\/NEJMOA2405922"},{"key":"1393_CR95","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","volume":"142","author":"DC Tong","year":"2020","unstructured":"Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050771.","journal-title":"Circulation"},{"key":"1393_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2023-079061","author":"J Li","year":"2024","unstructured":"Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024. https:\/\/doi.org\/10.1136\/BMJ-2023-079061.","journal-title":"BMJ"},{"key":"1393_CR97","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","volume":"404","author":"P Kelly","year":"2024","unstructured":"Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. 2024;404:125. https:\/\/doi.org\/10.1016\/S0140-6736(24)00968-1.","journal-title":"Lancet"},{"key":"1393_CR98","doi-asserted-by":"publisher","unstructured":"Tucker B, Tucker WJ, Chung JS, Figtree GA, Keech A, Patel S. The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease - A systematic review and meta-analysis. Eur J Prev Cardiol. Eur J Prev Cardiol; 2025;zwaf302. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF302","DOI":"10.1093\/EURJPC\/ZWAF302"},{"key":"1393_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120448","volume":"408","author":"AM Hagag","year":"2025","unstructured":"Elsevier Ireland Ltd, Hagag AM, Ghanem OA, khalaf MM, Ads ME, yassin Z, et al. Colchicine in the secondary prevention of stroke and major cardiovascular events in patients with stroke or at high risk of it: systematic review and meta-analysis. Atherosclerosis. 2025;408:120448. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120448.","journal-title":"Atherosclerosis"},{"key":"1393_CR100","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401:1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(23)00215-5.","journal-title":"Lancet"},{"key":"1393_CR101","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMOA2405182","volume":"391","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee I-M, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med. 2024;391:2087\u201397. https:\/\/doi.org\/10.1056\/NEJMOA2405182.","journal-title":"N Engl J Med"},{"key":"1393_CR102","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1093\/EURHEARTJ\/EHAF209","volume":"46","author":"JM Kraaijenhof","year":"2025","unstructured":"Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, Hovingh GK, et al. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. Eur Heart J. 2025;46:3875. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAF209.","journal-title":"Eur Heart J"},{"key":"1393_CR103","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1093\/EURHEARTJ\/EHAF281","volume":"46","author":"MRP Markus","year":"2025","unstructured":"Markus MRP, Ittermann T, Mari\u00f1o Coronado J, Schipf S, Bahls M, K\u00f6nemann S, et al. LDL-cholesterol, lipoprotein(a) and high-sensitivity low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J Eur Heart J. 2025;46:3863\u201374. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAF281.","journal-title":"Eur Heart J Eur Heart J"},{"key":"1393_CR104","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","volume":"44","author":"N Potere","year":"2024","unstructured":"Potere N, Bonaventura A, Abbate A. Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases. Arterioscler Thromb Vasc Biol. 2024;44:2371\u201395. https:\/\/doi.org\/10.1161\/ATVBAHA.124.319980.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-022-02446-6","volume":"20","author":"MK Georgakis","year":"2022","unstructured":"Georgakis MK, Malik R, Richardson TG, Howson JMM, Anderson CD, Burgess S, et al. Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups. BMC Med. 2022;20:245. https:\/\/doi.org\/10.1186\/S12916-022-02446-6.","journal-title":"BMC Med"},{"key":"1393_CR106","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/BCP.15191","volume":"88","author":"AJ Cupido","year":"2022","unstructured":"Cupido AJ, Asselbergs FW, Natarajan P, Ridker PM, Hovingh GK, Schmidt AF. Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R. Br J Clin Pharmacol. 2022;88:2875\u201384. https:\/\/doi.org\/10.1111\/BCP.15191.","journal-title":"Br J Clin Pharmacol"},{"key":"1393_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAB107","volume":"42","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Kleber ME, M\u00e4rz W, Pang S, Zewinger S, Triem S, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021;42:1742. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB107.","journal-title":"Eur Heart J"},{"key":"1393_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105786","volume":"117","author":"S Rostamian","year":"2025","unstructured":"Elsevier B.V., Rostamian S, Kaura A, Chrysostomou P, Welsh P, Ariti C, et al. The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause mortality over 20 years. EBioMedicine. 2025;117:105786. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105786.","journal-title":"EBioMedicine"},{"key":"1393_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117461","volume":"390","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Vasques-N\u00f3voa F, Neves JS, Zannad F, Leite-Moreira A, Elsevier Ireland Ltd. Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: findings from the MESA study. Atherosclerosis. 2024;390:117461. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117461.","journal-title":"Atherosclerosis"},{"key":"1393_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.AMJCARD.2023.03.025","volume":"197","author":"PM Burger","year":"2023","unstructured":"Burger PM, Pradhan AD, Dorresteijn JAN, Koudstaal S, Teraa M, de Borst GJ, et al. C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations. Am J Cardiol. 2023;197:13\u201323. https:\/\/doi.org\/10.1016\/J.AMJCARD.2023.03.025.","journal-title":"Am J Cardiol"},{"key":"1393_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS12131775","volume":"12","author":"S Schulz","year":"2023","unstructured":"Schulz S, Rehm S, Schlitt A, Lierath M, L\u00fcdike H, Hofmann B, et al. C-reactive protein level and the genetic variant rs1130864 in the CRP gene as prognostic factors for 10-year cardiovascular outcome. Cells. 2023;12:1775. https:\/\/doi.org\/10.3390\/CELLS12131775.","journal-title":"Cells"},{"key":"1393_CR112","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","volume":"41","author":"PM Ridker","year":"2020","unstructured":"Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020;41:2952\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa160.","journal-title":"Eur Heart J"},{"key":"1393_CR113","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","volume":"82","author":"PM Burger","year":"2023","unstructured":"Burger PM, Koudstaal S, Mosterd A, Fiolet ATL, Teraa M, van der Meer MG, et al. C-reactive protein and risk of incident heart failure in patients with cardiovascular disease. J Am Coll Cardiol. 2023;82:414\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.035.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR114","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2337\/dc22-1353","volume":"46","author":"A Gedebjerg","year":"2023","unstructured":"Gedebjerg A, Bjerre M, Kjaergaard AD, Nielsen JS, Rungby J, Brandslund I, et al. CRP, C-peptide, and risk of first-time cardiovascular events and mortality in early type 2 diabetes: a Danish cohort study. Diabetes Care. 2023;46:1037\u201345. https:\/\/doi.org\/10.2337\/dc22-1353.","journal-title":"Diabetes Care"},{"key":"1393_CR115","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.2337\/dc22-0866","volume":"45","author":"A Koshino","year":"2022","unstructured":"Koshino A, Schechter M, Sen T, Vart P, Neuen BL, Neal B, et al. Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. Diabetes Care. 2022;45:2644\u201352. https:\/\/doi.org\/10.2337\/dc22-0866.","journal-title":"Diabetes Care"},{"key":"1393_CR116","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/JAMACARDIO.2021.3079","volume":"6","author":"G Batra","year":"2021","unstructured":"Batra G, Ghukasyan Lakic T, Lindb\u00e4ck J, Held C, White HD, Stewart RAH, et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA Cardiol. 2021;6:1440\u20135. https:\/\/doi.org\/10.1001\/JAMACARDIO.2021.3079.","journal-title":"JAMA Cardiol"},{"key":"1393_CR117","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","volume":"43","author":"PM Ridker","year":"2022","unstructured":"Ridker PM, Tuttle KR, Perkovic V, Libby P, Macfadyen JG. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J. 2022;43:4832\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehac444.","journal-title":"Eur Heart J"},{"key":"1393_CR118","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/eurjpc\/zwad197","volume":"30","author":"X Jia","year":"2023","unstructured":"Jia X, Buckley L, Sun C, Al Rifai M, Yu B, Nambi V, et al. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: atherosclerosis risk in communities study. Eur J Prev Cardiol. 2023;30:1731\u201340. https:\/\/doi.org\/10.1093\/eurjpc\/zwad197.","journal-title":"Eur J Prev Cardiol"},{"key":"1393_CR119","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/ATVBAHA.116.308834","volume":"37","author":"SJ Bernelot Moens","year":"2017","unstructured":"Bernelot Moens SJ, Verweij SL, Schnitzler JG, Stiekema LCA, Bos M, Langsted A, et al. Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans. Arterioscler Thromb Vasc Biol. 2017;37:969\u201375. https:\/\/doi.org\/10.1161\/ATVBAHA.116.308834.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1393_CR120","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/J.JACC.2024.07.034","volume":"84","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Gummesson A, Taskinen MR, Burgess S, Packard CJ, et al. Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol. J Am Coll Cardiol. 2024;84:1328\u201338. https:\/\/doi.org\/10.1016\/J.JACC.2024.07.034.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR121","doi-asserted-by":"publisher","unstructured":"Kraaijenhof JM, Kerkvliet MJ, Nurmohamed NS, Grefhorst A, Kroon J, Wareham NJ, et al. The role of systemic inflammation in remnant cholesterol associated cardiovascular risk: insights from the EPIC-Norfolk study. Eur J Prev Cardiol. Eur J Prev Cardiol; 2025;zwaf037. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF037","DOI":"10.1093\/EURJPC\/ZWAF037"},{"key":"1393_CR122","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","volume":"77","author":"S Raposeiras-Roubin","year":"2021","unstructured":"Raposeiras-Roubin S, Rossell\u00f3 X, Oliva B, Fern\u00e1ndez-Friera L, Mendiguren JM, Andr\u00e9s V, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol. 2021;77:3031\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.059.","journal-title":"J Am Coll Cardiol"},{"key":"1393_CR123","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jacl.2023.01.007","volume":"17","author":"FY Cesena","year":"2023","unstructured":"Cesena FY, Generoso G, Santos RD, Pereira AC, Blaha MJ, Jones SR, et al. The association between triglyceride-rich lipoproteins, circulating leukocytes, and low-grade inflammation: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Lipidol. 2023;17:261\u201371. https:\/\/doi.org\/10.1016\/j.jacl.2023.01.007.","journal-title":"J Clin Lipidol"},{"key":"1393_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119241","volume":"406","author":"D El\u00edas-L\u00f3pez","year":"2025","unstructured":"El\u00edas-L\u00f3pez D, Kobylecki CJ, Vedel-Krogh S, Doi T, Nordestgaard BG. Association of low-grade inflammation and elevated remnant cholesterol with risk of ASCVD and mortality in impaired renal function. Atherosclerosis. 2025;406:119241. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119241.","journal-title":"Atherosclerosis"},{"key":"1393_CR125","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2021.06.907","volume":"330","author":"HH Liu","year":"2021","unstructured":"Liu HH, Li S, Cao YX, Guo YL, Zhu CG, Wu NQ, et al. Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis. 2021;330:29\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.06.907.","journal-title":"Atherosclerosis"},{"key":"1393_CR126","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jacl.2022.09.005","volume":"16","author":"PA Chevli","year":"2022","unstructured":"Chevli PA, Islam T, Pokharel Y, Rodriguez F, Virani SS, Blaha MJ, et al. Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Lipidol. 2022;16:870\u20137. https:\/\/doi.org\/10.1016\/j.jacl.2022.09.005.","journal-title":"J Clin Lipidol"},{"key":"1393_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131946","volume":"405","author":"CC Xiong","year":"2024","unstructured":"Xiong CC, Gao F, Zhang JH, Ruan Y, Gao TG, Cai JY, et al. Investigating the impact of remnant cholesterol on new-onset stroke across diverse inflammation levels: insights from the China health and retirement longitudinal study (CHARLS). Int J Cardiol. 2024;405:131946. https:\/\/doi.org\/10.1016\/j.ijcard.2024.131946.","journal-title":"Int J Cardiol"},{"key":"1393_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/S12944-025-02627-1","volume":"24","author":"F Kamrani","year":"2025","unstructured":"Kamrani F, Rezaee A, Bigdeloo L, Naseh Mojdehi A, Darroudi S, Hossein Talebkhah M, et al. Concordant and discordant roles of remnant cholesterol and hs-CRP in cardiovascular disease; gender stratified analysis. Lipids Health Dis. 2025;24:211. https:\/\/doi.org\/10.1186\/S12944-025-02627-1.","journal-title":"Lipids Health Dis"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01393-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:14:31Z","timestamp":1772442871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01393-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01393-4","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies with human or animal subjects are published and followed ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"30"}}